AN2 Therapeutics is rated a speculative buy with a valuation target of about $12 per share, compared to its recent price of $5.05. The company’s drug epetraborole failed as a treatment for refractory MAC lung disease but shows promise for treating polycythemia vera by reducing red blood cell parameters in a dose-dependent and reversible way. Early human and primate data support this potential, but further trials must prove it can control hematocrit and reduce the need for phlebotomy without causing serious anemia. Risks include prior drug efficacy issues, licensing obligations, uncertain patent protection, and possible dilution, though additional programs targeting M. abscessus and Chagas disease offer extra opportunities.
AN2 Therapeutics and its drug development are the subject, with Pluang's health sector data providing market context. Of 101 priced health-sector US stocks on Pluang, 54 rose and 41 fell today. Notable movers include FLNA at USD 0.93 with a 25.90% increase and WGS at USD 91.15 with a 6.83% decrease, as of Sep 22, 2026 20:31 WIB.
MillerKnoll reported a strong Q1 2027 earnings per share (EPS) of $0.53, surpassing analyst expectations by over 51%, helped by tariff refunds and improved cost management. However, its revenue fell 3.4% year-over-year to $923.40 million, missing est...
THOR Industries reported Q4 earnings with an EPS of $0.78, missing analyst estimates and showing a 66.9% drop from last year. Despite this, the company beat revenue expectations with $2.31 billion, though revenue declined 8.4% year-over-year due to w...
Cracker Barrel Old Country Store is set to report its Q3 2026 earnings on September 23, with analysts predicting a significant decline. Earnings per share are expected to fall to $0.17 from $0.74 last year, and revenue is forecasted around $834.57 mi...
Salesforce's AI-driven Agentforce business is expanding at over 240% annual recurring revenue growth, yet its stock trades like a legacy CRM company, down 9.6% year-to-date. The company reported strong Q2 FY27 results with $11.35 billion revenue and ...
Stellar (XLM) has broken above its 50-week moving average, signaling strong buying momentum and setting a trading range around $0.2123 to $0.2151, with potential to reach $0.2227 if demand continues. Meanwhile, XRP faces strong selling pressure near ...
